AUSTIN, Texas, June 4, 2024 /PRNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announced the establishment of an associated drug development accelerator called AS2Bio Inc. The company is creating a drug development ecosystem to bring transformative therapeutics to those living with Angelman syndrome (AS).